These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 33734721)
1. Engineered Antibody Fragment against the Urokinase Plasminogen Activator for Fast Delineation of Triple-Negative Breast Cancer by Positron Emission Tomography. Lu W; Cong Y; Yang D; Chen D; Yang G; Wang Y; Van Dort ME; Ross BD; Mazar AP; Chu BB; Hong H Mol Pharm; 2021 Apr; 18(4):1690-1698. PubMed ID: 33734721 [TBL] [Abstract][Full Text] [Related]
2. Antibody-based PET of uPA/uPAR signaling with broad applicability for cancer imaging. Yang D; Severin GW; Dougherty CA; Lombardi R; Chen D; Van Dort ME; Barnhart TE; Ross BD; Mazar AP; Hong H Oncotarget; 2016 Nov; 7(45):73912-73924. PubMed ID: 27729618 [TBL] [Abstract][Full Text] [Related]
3. Positron emission tomography imaging of tumor angiogenesis with a (61/64)Cu-labeled F(ab')(2) antibody fragment. Hong H; Zhang Y; Orbay H; Valdovinos HF; Nayak TR; Bean J; Theuer CP; Barnhart TE; Cai W Mol Pharm; 2013 Feb; 10(2):709-16. PubMed ID: 23316869 [TBL] [Abstract][Full Text] [Related]
4. Optimization of IGF-1R SPECT/CT imaging using 111In-labeled F(ab')2 and Fab fragments of the monoclonal antibody R1507. Heskamp S; van Laarhoven HW; Molkenboer-Kuenen JD; Bouwman WH; van der Graaf WT; Oyen WJ; Boerman OC Mol Pharm; 2012 Aug; 9(8):2314-21. PubMed ID: 22747077 [TBL] [Abstract][Full Text] [Related]
5. MicroPET/CT imaging of patient-derived pancreatic cancer xenografts implanted subcutaneously or orthotopically in NOD-scid mice using (64)Cu-NOTA-panitumumab F(ab')2 fragments. Boyle AJ; Cao PJ; Hedley DW; Sidhu SS; Winnik MA; Reilly RM Nucl Med Biol; 2015 Feb; 42(2):71-7. PubMed ID: 25456837 [TBL] [Abstract][Full Text] [Related]
6. Kang L; Li C; Yang Q; Sutherlin L; Wang L; Chen Z; Becker KV; Huo N; Qiu Y; Engle JW; Wang R; He C; Jiang D; Xu X; Cai W Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1470-1481. PubMed ID: 34677626 [TBL] [Abstract][Full Text] [Related]
7. Glypican-3-targeting F(ab')2 for 89Zr PET of hepatocellular carcinoma. Sham JG; Kievit FM; Grierson JR; Chiarelli PA; Miyaoka RS; Zhang M; Yeung RS; Minoshima S; Park JO J Nucl Med; 2014 Dec; 55(12):2032-7. PubMed ID: 25359880 [TBL] [Abstract][Full Text] [Related]
8. Antibody Fragment F(ab') Li Q; Peterson N; Hanna RN; Kuszpit K; White J; Allen KL; Barnes A; Rickert KW; Shan L; Wu H; Dall'Acqua WF; Tsui P; Borrok MJ Mol Pharm; 2020 Feb; 17(2):507-516. PubMed ID: 31841002 [TBL] [Abstract][Full Text] [Related]
9. Noninvasive Evaluation of CD20 Expression Using Kang L; Li C; Rosenkrans ZT; Engle JW; Wang R; Jiang D; Xu X; Cai W J Nucl Med; 2021 Mar; 62(3):372-378. PubMed ID: 32826320 [TBL] [Abstract][Full Text] [Related]
10. Tumor targeting properties of indium-111 labeled genetically engineered Fab' and F(ab')2 constructs of chimeric tumor necrosis treatment (chTNT)-3 antibody. Khawli LA; Alauddin MM; Hu P; Epstein AL Cancer Biother Radiopharm; 2003 Dec; 18(6):931-40. PubMed ID: 14969605 [TBL] [Abstract][Full Text] [Related]
11. PET of hypoxia with 89Zr-labeled cG250-F(ab')2 in head and neck tumors. Hoeben BA; Kaanders JH; Franssen GM; Troost EG; Rijken PF; Oosterwijk E; van Dongen GA; Oyen WJ; Boerman OC; Bussink J J Nucl Med; 2010 Jul; 51(7):1076-83. PubMed ID: 20554724 [TBL] [Abstract][Full Text] [Related]
12. Targeting human prostate cancer with 111In-labeled D2B IgG, F(ab')2 and Fab fragments in nude mice with PSMA-expressing xenografts. Lütje S; van Rij CM; Franssen GM; Fracasso G; Helfrich W; Eek A; Oyen WJ; Colombatti M; Boerman OC Contrast Media Mol Imaging; 2015; 10(1):28-36. PubMed ID: 24764162 [TBL] [Abstract][Full Text] [Related]
13. Cheng Y; Shi D; Xu Z; Gao Z; Si Z; Zhao Y; Ye R; Fu Z; Fu W; Yang T; Xiu Y; Lin Q; Cheng D Mol Pharm; 2022 Oct; 19(10):3551-3562. PubMed ID: 35244407 [TBL] [Abstract][Full Text] [Related]
14. Preparation, characterization, and in vivo biodistribution properties of synthetically cross-linked multivalent antitumor antibody fragments. Schott ME; Frazier KA; Pollock DK; Verbanac KM Bioconjug Chem; 1993; 4(2):153-65. PubMed ID: 7873647 [TBL] [Abstract][Full Text] [Related]
15. Monoclonal antibody Fab' fragment cross-linking using equilibrium transfer alkylation reagents. A strategy for site-specific conjugation of diagnostic and therapeutic agents with F(ab')2 fragments. Wilbur DS; Stray JE; Hamlin DK; Curtis DK; Vessella RL Bioconjug Chem; 1994; 5(3):220-35. PubMed ID: 7918742 [TBL] [Abstract][Full Text] [Related]
16. Biodistribution properties of (111)indium-labeled C-functionalized trans-cyclohexyl diethylenetriaminepentaacetic acid humanized 3S193 diabody and F(ab')(2) constructs in a breast carcinoma xenograft model. Tahtis K; Lee FT; Smyth FE; Power BE; Renner C; Brechbiel MW; Old LJ; Hudson PJ; Scott AM Clin Cancer Res; 2001 Apr; 7(4):1061-72. PubMed ID: 11309358 [TBL] [Abstract][Full Text] [Related]
17. Noninvasive localization of experimental atherosclerotic lesions with mouse/human chimeric Z2D3 F(ab')2 specific for the proliferating smooth muscle cells of human atheroma. Imaging with conventional and negative charge-modified antibody fragments. Narula J; Petrov A; Bianchi C; Ditlow CC; Lister BC; Dilley J; Pieslak I; Chen FW; Torchilin VP; Khaw BA Circulation; 1995 Aug; 92(3):474-84. PubMed ID: 7634463 [TBL] [Abstract][Full Text] [Related]
18. The strength of small: improved targeting of insulin-like growth factor-1 receptor (IGF-1R) with F(ab')₂-R1507 fragments in Ewing sarcomas. Fleuren ED; Versleijen-Jonkers YM; Heskamp S; Roeffen MH; Bouwman WH; Molkenboer-Kuenen JD; van Laarhoven HW; Oyen WJ; Boerman OC; van der Graaf WT Eur J Cancer; 2013 Sep; 49(13):2851-8. PubMed ID: 23664098 [TBL] [Abstract][Full Text] [Related]
19. A cross-linked monoclonal antibody fragment for improved tumor targeting. Stalteri MA; Mather SJ Bioconjug Chem; 1995; 6(2):179-86. PubMed ID: 7599261 [TBL] [Abstract][Full Text] [Related]